Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE).
Journal Paper/Review - Jul 15, 2022
Sudano Isabella, Mach François, Moccetti Tiziano, Burkard Thilo, Fahe Christian, Delabays Alain, Rickli Hans, Keller Pierre-Fréderic, Dopheide Jörn, Bodenmann Sereina, Fiolka Tom, Ehret Georg, Spirk David
Low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). In confirmatory trials, proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab substantially lowered LDL-C and reduced cardiovascular morbidity and mortality. However, the routine clinical use of alirocumab in Switzerland has not yet been studied.